PEPTIDE CORTEXThe library
← The library

Liraglutide

Saxenda/VictozaMetabolic/Weight
Evidence grade
AFDA-approved Rx (labeled use)
Cardiovascular · 0–5 · separate axis
5
Read first · not dosing instructions

Educational and research reference only. Not medical advice, not a recommendation, and not dosing instructions for any person. Figures are reported from the cited source and may be wrong or out of date. Research peptides are not approved for human use. Adults 18+. Consult a licensed physician before any decision about your health.

PurposeMetabolic / Weight loss
MechanismGLP-1 receptor agonist: reduces appetite and improves glycemic control
EffectsLess hunger, slower digestion, better blood sugar; often improves BP and overall CV risk
Dosing0.6 mg daily titration up to 3 mg daily (Saxenda)
Bottom lineStrongest data when used for its labeled indication under clinician guidance.
Protocols · as published1 sourced
FDA labelSaxenda
RouteSubcutaneous injection
FrequencyOnce daily
Starting0.6 mg daily, week 1
Escalation1.2 mg week 2, 1.8 mg week 3, 2.4 mg week 4
Target3 mg daily from week 5 (adults and pediatric patients)
Maximum3 mg daily. Adults who cannot tolerate 3 mg: discontinue.

Adults: stop if at least 4% of baseline body weight has not been lost (evaluated at 16 weeks). Pediatric patients who do not tolerate 3 mg may drop to 2.4 mg. Read through a summary of the FDA SPL, not a line-by-line read.

Batches on filenone

No tested batches on file.

Read with10
Cautions & interactions

GI side effects; pancreatitis; gallbladder disease; thyroid C-cell tumor warning

Caution with insulin/sulfonylureas (hypoglycemia risk); delays gastric emptying may affect absorption of oral meds; monitor for dehydration if on diuretics.

CV 5 of 5 — Strong human outcomes data via diabetes/obesity trials; improves multiple CV risk factors (weight, glucose, BP).